8-K: Checkpoint Therapeutics Announces Full-Year 2023 Financial Results and Provides Corporate Update

Checkpoint Therapeutics reported its 2023 financial results, highlighted by a decrease in net loss and progress towards resubmitting its Biologics License Application (BLA) for cosibelimab.

Summary

• Checkpoint Therapeutics announced its financial results for the year ended December 31, 2023, along with recent corporate updates.
• The company is working to resolve issues identified in a Complete Response Letter (CRL) from the FDA regarding its cosibelimab BLA.
• Checkpoint aims to resubmit the BLA for cosibelimab by mid-year 2024, targeting potential marketing approval before the end of the year.
• The company is also preparing for a potential commercial launch of cosibelimab.
• Checkpoint secured a new patent for cosibelimab covering a method of treating various cancers.
• The company published positive results from a pivotal trial of cosibelimab in the Journal for ImmunoTherapy of Cancer.
• Longer-term data for cosibelimab showed a deepening of response over time, with higher complete response rates than previously reported.
• New pharmacokinetic data supports an every-three-week dosing regimen for cosibelimab.
• Checkpoint raised approximately $47.6 million through registered direct offerings and private placements in 2023 and early 2024.
• The company's cash and cash equivalents totaled $4.9 million as of December 31, 2023, but this does not include a $14 million raise in January 2024.
• Research and development expenses decreased to $43.6 million in 2023 from $49.8 million in 2022.
• The net loss for 2023 was $51.8 million, or $3.17 per share, compared to a net loss of $62.6 million, or $7.09 per share, in 2022.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the progress in addressing the CRL and the positive clinical data, but tempered by the delay in approval and the company's financial situation.

Positives

• The company is actively working to address the issues raised in the FDA's Complete Response Letter (CRL).
• Checkpoint is targeting a BLA resubmission for cosibelimab by mid-year 2024, with potential marketing approval before the end of the year.
• The company secured a new patent for cosibelimab, providing protection through at least May 2038.
• Longer-term data for cosibelimab showed a deepening of response over time, with higher complete response rates.
• The company successfully raised $47.6 million through registered direct offerings and private placements.
• The net loss decreased from $62.6 million in 2022 to $51.8 million in 2023.
• Research and development expenses decreased by $6.2 million year-over-year.

Negatives

• The FDA issued a Complete Response Letter (CRL) for the cosibelimab BLA, citing issues at a third-party contract manufacturing organization.
• The company's cash and cash equivalents decreased from $12.1 million at the end of 2022 to $4.9 million at the end of 2023.
• The company reported a net loss of $51.8 million for the year ended December 31, 2023.

Risks

• The company faces the risk that the FDA may not accept the resubmitted BLA for cosibelimab.
• There is a risk that the clinical results from the Phase 1 clinical trial will not support regulatory approval of cosibelimab.
• The company is dependent on third-party suppliers and contract manufacturing relationships.
• Checkpoint needs substantial additional funds to continue operations.
• The company faces risks related to government regulation, patent and intellectual property matters, and competition.
• Unfavorable market or other economic conditions could impact the company's performance.
• The evolving and unpredictable Russia/Ukraine conflict and COVID-19 pandemic could delay the achievement of milestones.

Future Outlook

Checkpoint is targeting a BLA resubmission for cosibelimab by mid-year 2024 and anticipates potential marketing approval before the end of 2024. The company is also preparing for a potential commercial launch of cosibelimab.

Management Comments

• James F. Oliviero, President and Chief Executive Officer of Checkpoint, said, 'We continue to work closely with our third-party contract manufacturing organization to expeditiously resolve the deficiencies noted in the complete response letter (CRL) we received last December, and are targeting a Biologics License Application (BLA) resubmission for cosibelimab by mid-year to potentially obtain marketing approval before the end of 2024.'
• James F. Oliviero also stated, 'We remain highly confident in the clinical data and safety package in support of cosibelimab.'

Industry Context

This announcement is relevant to the oncology and immunotherapy sectors, particularly companies developing treatments for solid tumor cancers. The focus on cosibelimab, an anti-PD-L1 antibody, places Checkpoint in competition with other companies developing similar therapies. The company's progress towards resubmitting its BLA is a key development for its competitive position.

Comparison to Industry Standards

• Checkpoint's cosibelimab is being developed as a potential competitor to existing anti-PD-1/PD-L1 therapies such as Keytruda (pembrolizumab) from Merck and Opdivo (nivolumab) from Bristol Myers Squibb.
• The reported objective response rates of 55% in locally advanced cSCC and 50% in metastatic cSCC are competitive with other treatments in this space, although direct comparisons are difficult without head-to-head trial data.
• The company's focus on addressing manufacturing issues highlighted in the CRL is critical, as manufacturing quality is a key factor in regulatory approvals for biologics.
• The financial results show a decrease in net loss year-over-year, which is a positive sign, but the company's cash position remains a concern, as it is common for clinical-stage biotech companies to require additional funding.

Management Changes

Related Party Transactions

• The company reported revenue from a related party of $103,000 in 2023 and $192,000 in 2022.
• The company also reported accounts payable and accrued expenses to a related party of $2,815,000 in 2023 and $1,306,000 in 2022.

Stakeholder Impact

• Shareholders may be impacted by the delay in cosibelimab approval and the company's financial performance.
• Employees are likely impacted by the company's progress and financial stability.
• Patients with cSCC may benefit from the potential approval of cosibelimab.
• Suppliers and creditors are impacted by the company's financial health and ability to meet obligations.

Next Steps

• Checkpoint will work to resolve the deficiencies noted in the Complete Response Letter (CRL).
• The company plans to resubmit the Biologics License Application (BLA) for cosibelimab by mid-year 2024.
• Checkpoint will continue to execute on commercial launch preparation activities.
• The company will provide additional updates in the second quarter.

Key Dates

Keywords

cosibelimab, cutaneous squamous cell carcinoma, cSCC, BLA, FDA, checkpoint therapeutics, oncology, immunotherapy, clinical trial, patent, financial results